These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 14524646)

  • 1. Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions.
    Tsikouris JP; Cox CD
    Pharmacotherapy; 2003 Sep; 23(9):1141-52. PubMed ID: 14524646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulating atherosclerosis through inhibition or blockade of angiotensin.
    Rosenson RS
    Clin Cardiol; 2003 Jul; 26(7):305-11. PubMed ID: 12862295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
    Werner C; Baumhäkel M; Teo KK; Schmieder R; Mann J; Unger T; Yusuf S; Böhm M
    Clin Res Cardiol; 2008 Jul; 97(7):418-31. PubMed ID: 18454336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA
    Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature.
    Hammoud RA; Vaccari CS; Nagamia SH; Khan BV
    Vasc Health Risk Manag; 2007; 3(6):937-45. PubMed ID: 18200812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-ischemic potential of drugs related to the renin-angiotensin system.
    Ertl G; Hu K
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S11-20. PubMed ID: 11392474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blockers: evidence for preserving target organs.
    Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
    Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin antagonism in coronary artery disease: results after coronary revascularisation.
    Ribichini F; Ferrero V; Rognoni A; Vacca G; Vassanelli C
    Drugs; 2005; 65(8):1073-96. PubMed ID: 15907144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme inhibitors in patients with coronary atherosclerosis.
    Pitt B
    Am Heart J; 1994 Dec; 128(6 Pt 2):1328-32. PubMed ID: 7977014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?
    Ruschitzka FT; Lüscher TF
    Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical use of angiotensin-converting enzyme inhibitors.
    Wong J; Patel RA; Kowey PR
    Prog Cardiovasc Dis; 2004; 47(2):116-30. PubMed ID: 15586352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
    Enseleit F; Hürlimann D; Lüscher TF
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
    Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
    J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Angiotensin receptor blockers in cardiovascular disease.
    Maggioni AP
    Cardiovasc Drugs Ther; 2006 Aug; 20(4):295-308. PubMed ID: 16915347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5).
    Leong DP; McMurray JJV; Joseph PG; Yusuf S
    J Am Coll Cardiol; 2019 Aug; 74(5):683-698. PubMed ID: 31370961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
    Ball SG; White WB
    Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
    Catalá-López F; Macías Saint-Gerons D; González-Bermejo D; Rosano GM; Davis BR; Ridao M; Zaragoza A; Montero-Corominas D; Tobías A; de la Fuente-Honrubia C; Tabarés-Seisdedos R; Hutton B
    PLoS Med; 2016 Mar; 13(3):e1001971. PubMed ID: 26954482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.